Tatsuo Kanda, Reina Sasaki-Tanaka, Shuji Terai. Inflammation of the liver, HCC development and HCC establishment. Hepatology International. 2024
Tatsuo Kanda, Tian-Cheng Li, Masaharu Takahashi, Shigeo Nagashima, Putu Prathiwi Primadharsini, Satoshi Kunita, Reina Sasaki-Tanaka, Jun Inoue, Atsunori Tsuchiya, Shingo Nakamoto, et al. Recent advances in hepatitis E virus research and the Japanese clinical practice guidelines for hepatitis E virus infection. Hepatology research : the official journal of the Japan Society of Hepatology. 2024
Tatsuo Kanda, Reina Sasaki-Tanaka, Shuji Terai. Liver Diseases: From Bench to Bedside. International Journal of Molecular Sciences. 2024. 25. 10. 5454
Tatsuo Kanda, Reina Sasaki-Tanaka, Koji Ishii, Ryosuke Suzuki, Jun Inoue, Atsunori Tsuchiya, Shingo Nakamoto, Ryuzo Abe, Keiichi Fujiwara, Osamu Yokosuka, et al. Recent advances in hepatitis A virus research and clinical practice guidelines for hepatitis A virus infection in Japan. Hepatology research : the official journal of the Japan Society of Hepatology. 2024. 54. 1. 4-23
Rei Hirano, Tatsuo Kanda, Masayuki Honda, Shuhei Arima, Mai Totsuka, Ryota Masuzaki, Shini Kanezawa, Reina Sasaki-Tanaka, Naoki Matsumoto, Hiroaki Yamagami, et al. Hepatitis E Virus Infection Caused Elevation of Alanine Aminotransferase Levels in a Patient with Chronic Hepatitis B and Choledocholithiasis. Reports. 2023. 6. 4. 55-55
Tatsuo Kanda, Shingo Nakamoto, Reina Sasaki, Yuki Haga, Masato Nakamura, Shin Yasui, Makoto Arai, Fumio Imazeki, Osamu Yokosuka. Assessment of serum hepatitis C virus RNA 24 weeks after the end of treatment using TaqMan PCR is more relevant than after 12 weeks for predicting sustained virological response by simeprevir-versus telaprevir-based triple therapy. HEPATOLOGY. 2015. 62. 807A-807A
Tatsuo Kanda, Shingo Nakamoto, Reina Sasaki, Yuki Haga, Masato Nakamura, Shin Yasui, Makoto Arai, Fumio Imazeki, Osamu Yokosuka. Assessment of serum hepatitis C virus RNA 24 weeks after the end of treatment using TaqMan PCR is more relevant than after 12 weeks for predicting sustained virological response by simeprevir-versus telaprevir-based triple therapy. HEPATOLOGY. 2015. 62. 807A-807A
Xia Jiang, Tatsuo Kanda, Shuang Wu, Yuki Haga, Reina Sasaki, Masato Nakamura, Shingo Nakamoto, Fumio Imazeki, Osamu Yokosuka. HCV NS5A blocks MG132-induced apoptosis in hepatocytes through the inhibition of NF-kappa B activation. HEPATOLOGY. 2014. 60. 647A-647A